
Ipsen has reported positive topline results from its phase 3 BEOND clinical programme evaluating Dysport (abobotulinumtoxinA) for the prevention of …
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

